Variability in the elimination of mianserin in elderly patients
- PMID: 2719901
- PMCID: PMC1379723
- DOI: 10.1111/j.1365-2125.1989.tb05392.x
Variability in the elimination of mianserin in elderly patients
Abstract
1. Two studies of the elimination of mianserin are reported. 2. In the first study, the oral clearance of mianserin was measured in 15 elderly patients at steady state. In a sub-group of eight patients who completed studies at two different doses there was evidence of enhanced oral clearance at the higher dose. 3. In the second study, the elimination half-life was estimated in 12 patients who were observed to have disproportionately high mianserin concentrations with respect to dose. All had half-lives greater than or equal to 2.5 days with a mean of 6 +/- 2.8 (s.d.) days. In six of the patients the profile of elimination was suggestive of saturable elimination. 4. The sparteine oxidation status was measured in seven of the patients showing slow mianserin elimination. Only one was a 'poor oxidiser' of sparteine, suggesting no concordance with this phenotype. 5. It is concluded that there is marked variability in the elimination of mianserin in elderly patients.
Similar articles
-
The pharmacokinetics of mianserin.Br J Clin Pharmacol. 1983;15 Suppl 2(Suppl 2):313S-322S. doi: 10.1111/j.1365-2125.1983.tb05880.x. Br J Clin Pharmacol. 1983. PMID: 6824562 Free PMC article.
-
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.Clin Pharmacol Ther. 1992 Mar;51(3):288-95. doi: 10.1038/clpt.1992.24. Clin Pharmacol Ther. 1992. PMID: 1531951
-
Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam.Eur J Clin Pharmacol. 1985;28(6):689-92. doi: 10.1007/BF00607917. Eur J Clin Pharmacol. 1985. PMID: 4065194
-
Serum mianserin and ageing.Prog Neuropsychopharmacol Biol Psychiatry. 1994 Sep;18(5):833-45. doi: 10.1016/0278-5846(94)90100-7. Prog Neuropsychopharmacol Biol Psychiatry. 1994. PMID: 7972855 Review.
-
Clinical pharmacokinetics of mirtazapine.Clin Pharmacokinet. 2000 Jun;38(6):461-74. doi: 10.2165/00003088-200038060-00001. Clin Pharmacokinet. 2000. PMID: 10885584 Review.
Cited by
-
Antidepressants in the elderly: challenges for study design and their interpretation.Br J Clin Pharmacol. 2000 Jun;49(6):539-47. doi: 10.1046/j.1365-2125.2000.00201.x. Br J Clin Pharmacol. 2000. PMID: 10848717 Free PMC article. Review.
-
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19902987
-
Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.Drugs Aging. 1998 Oct;13(4):269-80. doi: 10.2165/00002512-199813040-00003. Drugs Aging. 1998. PMID: 9805208 Review.
-
Adverse effects of antidepressants in the elderly.Drugs Aging. 1992 Sep-Oct;2(5):450-8. doi: 10.2165/00002512-199202050-00008. Drugs Aging. 1992. PMID: 1392225 Review.
-
Pharmacokinetic optimisation of therapy with newer antidepressants.Clin Pharmacokinet. 1994 Oct;27(4):307-30. doi: 10.2165/00003088-199427040-00005. Clin Pharmacokinet. 1994. PMID: 7834966 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources